Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Core binding factor acute myeloid leukemia (AML) comprises two subtypes with distinct cytogenetic abnormalities of either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since long-term response to chemotherapy in these leukemias is relatively good, allogeneic hematopoietic stem cell transpla...

Descripción completa

Detalles Bibliográficos
Autores principales: Halaburda, Kazimierz, Labopin, Myriam, Mailhol, Audrey, Socié, Gerard, Craddock, Charles, Aljurf, Mahmoud, Beelen, Dietrich, Cornelissen, Jan J., Bourhis, Jean-Henri, Labussière-Wallet, Hélène, Blaise, Didier, Gedde-Dahl, Tobias, Gilleece, Maria, Yakoub-Agha, Ibrahim, Mufti, Ghulam, Esteve, Jordi, Mohty, Mohamad, Nagler, Arnon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271580/
https://www.ncbi.nlm.nih.gov/pubmed/31439677
http://dx.doi.org/10.3324/haematol.2019.222810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271580/
https://www.ncbi.nlm.nih.gov/pubmed/31439677
http://dx.doi.org/10.3324/haematol.2019.222810

Ejemplares similares